Fasiplon

This classification denotes a sedative, hypnotic, and anxiolytic with the molecular formula C13H15N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier XCA050IPGB, chemically known as 6-ethyl-7-methoxy-5-methyl-2-(5-methyl-1,2,4-oxadiazol-3-yl)imidazo(1,2-a)pyrimidine. but generally known as fasiplon, which bears US NIH Compound Identifier 208954. European Medicines Agency schedules Fasiplon in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07514MIG. The term FASIPLON is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). FASIPLON is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule fasiplon under HS 29349990 and SITC 51579. As of Q4 2014, FASIPLON remains the US FDA Preferred Term for this commodity. Fasiplon bears US NLM identifiers UMLS ID C1880736 and NCI Concept Code C65622. SMILES: O(C1NC2N(C(C1CC)C)CC(N2)C1NC(ON1)C)C.